Anti-Hu CD105 PE

Anti-Hu CD105 PE
Regulatory status
RUO
Antigen
CD105
Clone
MEM-229
Format
PE
Reactivity
Pig, Human
Application
Excitation laser
blue (488 nm)
Variant
100 tests
1P-453-T100
In stock
242.00 USD

25 tests
1P-453-T025
In stock
121.00 USD
Variant
100 tests
1P-453-T100
In stock
242.00 USD

25 tests
1P-453-T025
In stock
121.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG2a
Specificity
The antibody MEM-229 recognizes an extracellular epitope of CD105 (Endoglin), a 90 kDa type I integral membrane homodimer glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy.
Application
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
Reactivity
Pig, Human
Negative species
Dog, Horse
Immunogen
Recombinant Vaccinia virus containing the human CD105 (L-isoform) cDNA.
Preparation
Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
Endoglin, END, ENG, HHT1, ORW1
Antigen description
CD105 (endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGFbetaR-2 as a receptor for TGFbeta-1 and TGFbeta-3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonises the inhibitory effects of TGFbeta-1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.
Entrez Gene ID 2022
UniProt ID P17813
1P-453 FC
Separation of HUVEC cells (red-filled) from HEK-293 cells (black-dashed) in flow cytometry analysis (surface staining) using anti-human CD105 (MEM-229) PE antibody (20 μl reagent per milion cells in 100 μl of cell suspension).

General references:

Zhu Y, Sun Y, Xie L, Jin K, Sheibani N, Greenberg DA: Hypoxic induction of endoglin via mitogen-activated protein kinases in mouse brain microvascular endothelial cells. Stroke. 2003 Oct;34(10):2483-8.
PubMed
Li C, Issa R, Kumar P, Hampson IN, Lopez-Novoa JM, Bernabeu C, Kumar S: CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci. 2003 Jul 1;116(Pt 13):2677-85.
PubMed
Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S: CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res. 2004 May-Jun;24(3a):1337-45.
PubMed
Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun;25(3B):1851-64.
PubMed
Piao M, Tokunaga O: Significant expression of endoglin (CD105), TGFbeta-1 and TGFbeta R-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb. 2006 Apr;13(2):82-9.
PubMed

Product specific references:

Plánka L, Necas A, Srnec R, Rauser P, Starý D, Jancár J, Amler E, Filová E, Hlucilová J, Kren L, Gál P: Use of allogenic stem cells for the prevention of bone bridge formation in miniature pigs. Physiol Res. 2009;58(6):885-93.
PubMed
Variant
100 tests
1P-453-T100
In stock
242.00 USD

25 tests
1P-453-T025
In stock
121.00 USD
Variant
100 tests
1P-453-T100
In stock
242.00 USD

25 tests
1P-453-T025
In stock
121.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-173
Reg. statusRUO
ApplicationFC, FC-IC
0.1 mg
198.00 USD